TR200301552A1 - Novel oral pharmacological formulations of rofecoxib. - Google Patents

Novel oral pharmacological formulations of rofecoxib.

Info

Publication number
TR200301552A1
TR200301552A1 TR2003/01552A TR200301552A TR200301552A1 TR 200301552 A1 TR200301552 A1 TR 200301552A1 TR 2003/01552 A TR2003/01552 A TR 2003/01552A TR 200301552 A TR200301552 A TR 200301552A TR 200301552 A1 TR200301552 A1 TR 200301552A1
Authority
TR
Turkey
Prior art keywords
rofecoxib
novel oral
pharmacological formulations
oral pharmacological
formulations
Prior art date
Application number
TR2003/01552A
Other languages
Turkish (tr)
Inventor
Uslu Abdullah
Original Assignee
Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. filed Critical Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş.
Priority to TR2003/01552A priority Critical patent/TR200301552A1/en
Priority to PCT/TR2004/000039 priority patent/WO2005025564A1/en
Publication of TR200301552A1 publication Critical patent/TR200301552A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bu buluş rofekoksib etken içeren ve bu etken maddenin oral yolla alınmasını sağlayan yeni farmasötik dozaj formlarını hazırlamak için geliştirilen yeni yöntem ile ilgilidir. Geliştirilen bu formülasyon ile rofekoksibin dissolüsyon ve invivo özelliklerine üstünlük kazandırılmıştır.The present invention relates to a novel method for preparing novel pharmaceutical dosage forms comprising rofecoxib agent and for oral administration thereof. With this formulation developed, dissolution and invivo properties of rofecoxib were improved.

TR2003/01552A 2003-09-18 2003-09-18 Novel oral pharmacological formulations of rofecoxib. TR200301552A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2003/01552A TR200301552A1 (en) 2003-09-18 2003-09-18 Novel oral pharmacological formulations of rofecoxib.
PCT/TR2004/000039 WO2005025564A1 (en) 2003-09-18 2004-09-16 Oral pharmaceutical formulations of rofecoxib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2003/01552A TR200301552A1 (en) 2003-09-18 2003-09-18 Novel oral pharmacological formulations of rofecoxib.

Publications (1)

Publication Number Publication Date
TR200301552A1 true TR200301552A1 (en) 2005-10-21

Family

ID=34311481

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/01552A TR200301552A1 (en) 2003-09-18 2003-09-18 Novel oral pharmacological formulations of rofecoxib.

Country Status (2)

Country Link
TR (1) TR200301552A1 (en)
WO (1) WO2005025564A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US10945992B1 (en) * 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284330B6 (en) * 1996-05-17 2005-01-03 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
EA008242B1 (en) * 1999-12-08 2007-04-27 Фармация Корпорейшн Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect and methods for treating diseases
AU2002236120A1 (en) * 2001-02-27 2002-09-12 Ranbaxy Laboratories Limited Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
WO2003086343A2 (en) * 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms

Also Published As

Publication number Publication date
WO2005025564A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
DK0954314T3 (en) Dosage forms for ameliorating male erectile dysfunction
SE0001899D0 (en) New compounds
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
EA200700049A1 (en) PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL
NO20025621D0 (en) Sustained release pharmaceutical composition for parenteral administration of hydrophilic compounds
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
CY1111698T1 (en) COMBINATION INCLUDING AN AT1 COMPETITIVE RECEPTOR AND AN INSULIN EXTRACTOR OR A INSULIN SENSITIVE
SE0102036D0 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
MX2007015480A (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption.
ATE292453T1 (en) ANTIVIRAL DRUG
SE0401342D0 (en) Therapeutic compounds
EA200901393A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE
TW200603787A (en) Topical preparations containing ambroxol
SE0102440D0 (en) New compound
BRPI0412430A (en) zot and zonulin receptor agonist polypeptide
BR0113165A (en) 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
HUP0203148A2 (en) Orally distintegrating composition comprising mirtazapine
BR0206960A (en) Oral pharmaceutical composition and use of a hydroxypropyl methylcellulose phthalate polymer
DE50005082D1 (en) Process for the production of powdery solubilizing aids for solid pharmaceutical dosage forms
TR200301553A1 (en) New oral pharmaceutical formulations containing irbesartan active ingredient
SE0001916D0 (en) Novel formulation
BRPI0413374A (en) weak base release compositions for an extended period of time
DK1268522T3 (en) LH-RH antagonists as well as their preparation and use thereof as drugs